SwePub
Sök i LIBRIS databas

  Utökad sökning

id:"swepub:oai:DiVA.org:uu-301113"
 

Sökning: id:"swepub:oai:DiVA.org:uu-301113" > Exploring the obsta...

  • Baraldi, EnricoUppsala universitet,Industriell teknik (författare)

Exploring the obstacles to implementing economic mechanisms to stimulate antibiotic research and development : a mulit-actor and system-level analysis

  • Artikel/kapitelEngelska2016

Förlag, utgivningsår, omfång ...

  • 2021-01-06
  • Boston :Boston University School of Law,2016
  • printrdacarrier

Nummerbeteckningar

  • LIBRIS-ID:oai:DiVA.org:uu-301113
  • https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-301113URI
  • https://doi.org/10.1177/0098858816658276DOI

Kompletterande språkuppgifter

  • Språk:engelska
  • Sammanfattning på:engelska

Ingår i deldatabas

Klassifikation

  • Ämneskategori:ref swepub-contenttype
  • Ämneskategori:art swepub-publicationtype

Anmärkningar

  • This Article examines the potential stakeholder-related obstacles hindering the implementation of mechanisms to re-ignite the development of novel antibiotics. Proposed economic models and incentives to drive such development include: Public Funding of Research and Development (R&D), Tax Incentives, Milestone Prizes, End Payments, Intellectual Property (IP) and Exclusivity Extensions, Pricing and Reimbursement Incentives, Product Development Partnerships (PDPs), and the Options Market for Antibiotics model. Drawing on personal experience and understanding of the antibiotic field, as well as stakeholder consultation and numerous expert meetings within the DRIVE-AB project and Uppsala Health Summit 2015, the Authors identify obstacles attributable to the following actors: Universities and Research Institutes, Small and Medium-sized Enterprises (SMEs), Large Pharmaceutical Companies, Marketing Approval Regulators, Payors, Healthcare Providers, National Healthcare Authorities, Patients, and Supranational Institutions. The analysis also proposes a characterization and ranking of the difficulty associated with implementing the reviewed mechanisms. Public Funding of R&D, Pricing and Reimbursement Incentives, and PDPs are mechanisms expected to meet highly systemic barriers (i.e., obstacles across the entire antibiotic value chain), imposing greater implementation challenges in that they require convincing and involving several motivationally diverse actors in order to have much effect.

Ämnesord och genrebeteckningar

  • Business Studies
  • Företagsekonomi
  • Engineering Science with specialization in industrial engineering and management
  • Teknisk fysik med inriktning mot industriell teknik

Biuppslag (personer, institutioner, konferenser, titlar ...)

  • Ciabuschi, FrancescoUppsala universitet,Företagsekonomiska institutionen(Swepub:uu)frcia027 (författare)
  • Leach, RossUniv Hosp Geneva, Infect Control Program, Geneva, Switzerland; Fac Med, Geneva, Switzerland (författare)
  • Morel, Chantal M.Univ Hosp Geneva, Infect Control Program, Geneva, Switzerland; Fac Med, Geneva, Switzerland; London Sch Econ & Polit Sci, London, England (författare)
  • Waluszewski, Alexandra,1956-Uppsala universitet,Centrum för teknik- och vetenskapstudier,STS(Swepub:uu)alexwalu (författare)
  • Uppsala universitetIndustriell teknik (creator_code:org_t)

Sammanhörande titlar

  • Ingår i:American Journal of Law & MedicineBoston : Boston University School of Law42, s. 451-4860098-85882375-835X

Internetlänk

Hitta via bibliotek

Till lärosätets databas

Sök utanför SwePub

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy